6533b851fe1ef96bd12aa2b0

RESEARCH PRODUCT

Decreased benzodiazepine receptor binding in panic disorder measured by IOMAZENIL-SPECT. A preliminary report.

R SchloesserA. BockischK HahnS SchlegelOtto BenkertH. Steinert

subject

AdultFlumazenilMalemedicine.medical_specialtymedicine.drug_classbehavioral disciplines and activitiesCerebral VentriclesInternal medicinemental disordersmedicineHumansPharmacology (medical)Biological PsychiatryBenzodiazepine receptor bindingTemporal cortexPsychiatric Status Rating ScalesTomography Emission-Computed Single-PhotonIomazenilBenzodiazepinePanic disorderPanicGeneral Medicinemedicine.diseaseReceptors GABA-AFrontal LobePsychiatry and Mental healthEndocrinologyFlumazenilAnesthesiaPanic DisorderFemaleOccipital Lobemedicine.symptomPsychologyAnxiety disordermedicine.drug

description

Single photon emission tomography (SPECT) imaging of the central benzodiazepine receptor (BZr) became possible with the newly developed ligand 123I-IOMAZENIL. The BZr binding was investigated in ten patients with panic disorder (PP) compared to ten epileptic patients (EP). Panic patients had lower IOMAZENIL uptake rates in the frontal, occipital and temporal cortex than EP indicating the involvement of the BZr complex in panic disorder.

yearjournalcountryeditionlanguage
1994-06-01European archives of psychiatry and clinical neuroscience
10.1007/bf02279812https://pubmed.ncbi.nlm.nih.gov/7918702